These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24294506)

  • 41. Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration.
    Truty MJ; Thomas RM; Katz MH; Vauthey JN; Crane C; Varadhachary GR; Wolff RA; Abbruzzese JL; Lee JE; Fleming JB
    J Am Coll Surg; 2012 Jul; 215(1):41-51; discussion 51-2. PubMed ID: 22608401
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
    Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
    BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intraoperative Electron Beam Radiation Therapy (IOERT) Versus High-Dose-Rate Intraoperative Brachytherapy (HDR-IORT) in Patients With an R1 Resection for Locally Advanced or Locally Recurrent Rectal Cancer.
    Voogt ELK; van Rees JM; Hagemans JAW; Rothbarth J; Nieuwenhuijzen GAP; Cnossen JS; Peulen HMU; Dries WJF; Nuyttens J; Kolkman-Deurloo IK; Verhoef C; Rutten HJT; Burger JWA
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1032-1043. PubMed ID: 33567303
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions.
    Wild AT; Hiniker SM; Chang DT; Tran PT; Khashab MA; Limaye MR; Laheru DA; Le DT; Kumar R; Pai JS; Hargens B; Sharabi AB; Shin EJ; Zheng L; Pawlik TM; Wolfgang CL; Koong AC; Herman JM
    J Gastrointest Oncol; 2013 Dec; 4(4):343-51. PubMed ID: 24294505
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multimodality therapy including surgical resection and intraoperative electron radiotherapy for recurrent or advanced primary carcinoma of the urinary bladder or ureter.
    Hallemeier CL; Karnes RJ; Pisansky TM; Davis BJ; Gunderson LL; Leibovich BC; Haddock MG; Choo R
    Am J Clin Oncol; 2013 Dec; 36(6):596-600. PubMed ID: 22868244
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Changing paradigm in pancreatic cancer: from adjuvant to neoadjuvant chemoradiation.
    Anderson JD; Wan W; Kaplan BJ; Myers J; Fields EC
    J Gastrointest Oncol; 2016 Dec; 7(6):1004-1010. PubMed ID: 28078125
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
    JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
    Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
    Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Results of irradiation or chemoirradiation for primary unresectable, locally recurrent, or grossly incomplete resection of gastric adenocarcinoma.
    Henning GT; Schild SE; Stafford SL; Donohue JH; Burch PA; Haddock MG; Gunderson LL
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):109-18. PubMed ID: 10656381
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy.
    Golcher H; Brunner T; Grabenbauer G; Merkel S; Papadopoulos T; Hohenberger W; Meyer T
    Eur J Surg Oncol; 2008 Jul; 34(7):756-64. PubMed ID: 18191528
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.
    Boone BA; Steve J; Krasinskas AM; Zureikat AH; Lembersky BC; Gibson MK; Stoller RG; Zeh HJ; Bahary N
    J Surg Oncol; 2013 Sep; 108(4):236-41. PubMed ID: 23955427
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer.
    Strobel O; Berens V; Hinz U; Hartwig W; Hackert T; Bergmann F; Debus J; Jäger D; Büchler MW; Werner J
    Surgery; 2012 Sep; 152(3 Suppl 1):S33-42. PubMed ID: 22770956
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.
    Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M
    Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intraoperative Electron Radiation Therapy Combined with External Beam Radiation Therapy after Gross Total Resection in Extremity Soft Tissue Sarcoma: A European Pooled Analysis.
    Roeder F; de Paoli A; Saleh-Ebrahimi L; Alldinger I; Bertola G; Boz G; Navarria F; Cuervo M; Uhl M; Alvarez A; Buechler M; Lehner B; Debus J; Calvo FA; Krempien R
    Ann Surg Oncol; 2018 Dec; 25(13):3833-3842. PubMed ID: 30276647
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer.
    Aristu J; Cañón R; Pardo F; Martínez-Monge R; Martin-Algarra S; Manuel Ordoñez J; Villafranca E; Moreno M; Cambeiro M; Azinovic I
    Am J Clin Oncol; 2003 Feb; 26(1):30-6. PubMed ID: 12576921
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
    Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
    Front Oncol; 2020; 10():41. PubMed ID: 32083002
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for locoregionally recurrent or locoregionally advanced primary renal cell carcinoma.
    Hallemeier CL; Choo R; Davis BJ; Pisansky TM; Gunderson LL; Leibovich BC; Haddock MG
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1938-43. PubMed ID: 21514065
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.
    Choong NW; Mauer AM; Haraf DC; Ferguson MK; Sandler AB; Kesler KA; Fishkin PA; Ansari RH; Wade J; Krauss SA; Sciortino DF; Posner MC; Kocherginsky M; Hoffman PC; Szeto L; Vokes EE
    Med Oncol; 2011 Dec; 28 Suppl 1():S152-61. PubMed ID: 20730572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.